Vienna
,
Austria
4 - 7 June 2025
European Renal Association (ERA 2025)
Presentation schedule and materials
Friday, 06 June 2025
09:21
- 09:27
CEST
ORAL PRESENTATION
SMART Stone MDT and patient care recommendations: The Nephrologist’s role in optimizing the adult high-risk kidney stone patient pathway
Pietro Manuel Ferraro1; Esteban Emiliani2,3; Thomas Knoll4; Giorgia Mandrile5; Gill Rumsby6; Bhaskar Somani7
MATERIALS AVAILABLE
15:00
- 15:18
CEST
ORAL PRESENTATION
Oral semaglutide and kidney outcomes in type 2 diabetes: A prespecified analysis of the SOUL randomised cardiovascular outcomes trial
Johannes F. E. Mann1; Nikolaus Marx2; John E. Deanfield3; Scott Emerson4; Silvio E. Inzucchi5; Darren K. McGuire6; Sharon L. Mulvagh7; Rodica Pop-Busui8; Neil Poulter9; Kirstine Brown-Frandsen10; Mads D. Engelmann10; G. Kees Hovingh10; Nicolas Belmar10; Thomas Idorn10; Ole Kleist Jeppesen10; Andreas L. Birkenfeld11; Aslam Amod12; Boris Mankovsky13; Cyrus Desouza14; Juan Jose Gorgojo Martinez15; Rosario Arechavaleta16; Shih Te Tu17; John B. Buse18; on behalf of the SOUL Study Group
MATERIALS AVAILABLE
15:36
- 15:54
CEST
ORAL PRESENTATION
Reduced kidney function decline with semaglutide across kidney risk categories: analyses from the FLOW trial
David Cherney1; Nicolas Belmar2; Trine Welløv Boesgaard2; Julie Funch Furberg2; Thomas Idorn2; Kenneth W. Mahaffey3; Johannes F. E. Mann4,5; Vlado Perkovic6; Richard E. Pratley7; Katherine R. Tuttle8,9; Peter Rossing10
MATERIALS AVAILABLE
15:54
- 16:12
CEST
ORAL PRESENTATION
Effects of semaglutide on KDIGO risk category in participants with type 2 diabetes and chronic kidney disease: The FLOW trial
Willem A. Bax1; Richard E. Pratley2; Kenneth W. Mahaffey3; Peter Rossing4; Søren Rasmussen5; Heidrun Bosch-Traberg5; Manuel Mayrdorfer5; Katherine R. Tuttle6,7
MATERIALS AVAILABLE
Keywords